JP7433222B2 - Ａｌｋ７結合タンパク質およびその使用 - Google Patents

Ａｌｋ７結合タンパク質およびその使用 Download PDF

Info

Publication number
JP7433222B2
JP7433222B2 JP2020523427A JP2020523427A JP7433222B2 JP 7433222 B2 JP7433222 B2 JP 7433222B2 JP 2020523427 A JP2020523427 A JP 2020523427A JP 2020523427 A JP2020523427 A JP 2020523427A JP 7433222 B2 JP7433222 B2 JP 7433222B2
Authority
JP
Japan
Prior art keywords
seq
alk7
amino acid
binding protein
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500895A5 (enExample
JP2021500895A (ja
Inventor
クマール，ラビンドラ
カストングアイ，ロゼリン
サコ，ダイアン
ベルク，ジョナサン
ジェイ． シャーキー，ネイサン
Original Assignee
アクセレロン ファーマ インコーポレーテッド
アディマブ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセレロン ファーマ インコーポレーテッド, アディマブ， エルエルシー filed Critical アクセレロン ファーマ インコーポレーテッド
Publication of JP2021500895A publication Critical patent/JP2021500895A/ja
Publication of JP2021500895A5 publication Critical patent/JP2021500895A5/ja
Priority to JP2023192144A priority Critical patent/JP2024023278A/ja
Application granted granted Critical
Publication of JP7433222B2 publication Critical patent/JP7433222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020523427A 2017-10-25 2018-10-25 Ａｌｋ７結合タンパク質およびその使用 Active JP7433222B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023192144A JP2024023278A (ja) 2017-10-25 2023-11-10 Ａｌｋ７結合タンパク質およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762577038P 2017-10-25 2017-10-25
US62/577,038 2017-10-25
PCT/US2018/057482 WO2019084249A1 (en) 2017-10-25 2018-10-25 ALK7 BINDING PROTEINS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023192144A Division JP2024023278A (ja) 2017-10-25 2023-11-10 Ａｌｋ７結合タンパク質およびその使用

Publications (3)

Publication Number Publication Date
JP2021500895A JP2021500895A (ja) 2021-01-14
JP2021500895A5 JP2021500895A5 (enExample) 2021-12-02
JP7433222B2 true JP7433222B2 (ja) 2024-02-19

Family

ID=66246796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523427A Active JP7433222B2 (ja) 2017-10-25 2018-10-25 Ａｌｋ７結合タンパク質およびその使用
JP2023192144A Withdrawn JP2024023278A (ja) 2017-10-25 2023-11-10 Ａｌｋ７結合タンパク質およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023192144A Withdrawn JP2024023278A (ja) 2017-10-25 2023-11-10 Ａｌｋ７結合タンパク質およびその使用

Country Status (9)

Country Link
US (2) US11981738B2 (enExample)
EP (1) EP3700571A4 (enExample)
JP (2) JP7433222B2 (enExample)
KR (1) KR20200089666A (enExample)
CN (1) CN111836642A (enExample)
AU (1) AU2018354295B2 (enExample)
BR (1) BR112020007751A2 (enExample)
CA (1) CA3079963A1 (enExample)
WO (1) WO2019084249A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501547B2 (en) 2016-04-22 2019-12-10 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
CA3079963A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof
AU2020282764A1 (en) * 2019-05-30 2021-12-02 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
JP7541709B2 (ja) * 2020-03-19 2024-08-29 株式会社CUBICStars タンパク質結合部位情報取得装置、タンパク質結合部位情報取得装置の作動方法及びプログラム

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
JP2001513652A (ja) 1997-06-06 2001-09-04 アサト アクチエンゲゼルシャフト アプライド サイエンス アンド テクノロジー 抗−ｇｐｉｉｂ／ｉｉｉａ組み換え抗体
AR055191A1 (es) 2005-10-12 2007-08-08 Morphosys Ag Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano
CA2896413A1 (en) 2008-12-05 2010-06-10 Abraxis Bioscience Llc Sparc binding peptides and uses thereof
AU2014368474A1 (en) 2013-12-19 2016-06-16 Arsanis Biosciences Gmbh Antibodies directed against the LukGH (LukAB) toxin of Staphylococcus aureus and antibody sequences
KR101644043B1 (ko) 2014-03-18 2016-08-01 한국과학기술원 Ｒｎａ에 특이적으로 결합하는 항체
US10501547B2 (en) 2016-04-22 2019-12-10 Acceleron Pharma Inc. ALK7 binding proteins and uses thereof
CA3079963A1 (en) 2017-10-25 2019-05-02 Acceleron Pharma Inc. Alk7 binding proteins and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Kogame M. et al.，ALK7 is a novel marker for adipocyte differentiation，The Journal of Medical Investigation，2006年，Vol. 53，pp. 238-245
Schlothauer T. et al.，Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions，Protein Engineering, Design & Selection，2016年，Vol. 29，pp. 457-466
Zhao F. et al.，Nodal induces apoptosis through activation of the ALK7 signaling pathway in pancreatic INS-1 β-cells，Am J Physiol Endocrinol Metab，2012年，Vol. 303，pp. E132-E143

Also Published As

Publication number Publication date
EP3700571A4 (en) 2021-07-28
CA3079963A1 (en) 2019-05-02
JP2024023278A (ja) 2024-02-21
US11981738B2 (en) 2024-05-14
BR112020007751A2 (pt) 2020-10-20
AU2018354295A1 (en) 2020-04-30
CN111836642A (zh) 2020-10-27
KR20200089666A (ko) 2020-07-27
JP2021500895A (ja) 2021-01-14
US20200392233A1 (en) 2020-12-17
WO2019084249A1 (en) 2019-05-02
EP3700571A1 (en) 2020-09-02
AU2018354295B2 (en) 2025-08-14
US20240287196A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
US20230416379A1 (en) ALK7 Binding Proteins and Uses Thereof
US12042524B2 (en) Activin type 2 receptor binding proteins methods of making them
KR20150136031A (ko) 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도
JP7433222B2 (ja) Ａｌｋ７結合タンパク質およびその使用
AU2020284038A1 (en) ActRII-binding proteins and uses thereof
JP7617036B2 (ja) Ａｌｋ７結合タンパク質及びその使用
CN116217731B (zh) Alk7结合蛋白及其用途
HK40003020B (en) Alk7 binding proteins and uses thereof

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20210910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211025

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240206

R150 Certificate of patent or registration of utility model

Ref document number: 7433222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350